SMAD4 alteration associates with invasive-front pathological markers and poor prognosis in colorectal cancer

Hidehito Oyanagi, Yoshifumi Shimada, Masayuki Nagahashi, Hiroshi Ichikawa, Yosuke Tajima, Kaoru Abe, Masato Nakano, Hitoshi Kameyama, Yasumasa Takii, Takashi Kawasaki, Kei Ichi Homma, Yiwei Ling, Shujiro Okuda, Kazuaki Takabe, Toshifumi Wakai

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aims: SMAD4 acts as a tumour suppressor, and the loss of SMAD4 is associated with poor prognosis in colorectal cancer (CRC) patients. Although next-generation sequencing (NGS) enabled us to detect numerous genetic alterations in a single assay, the clinical significance of SMAD4 alteration detected with NGS has not been fully investigated. The aim of this study was to evaluate the clinicopathological characteristics and clinical significance of SMAD4 alteration detected with NGS in CRC. Methods and results: We retrospectively investigated 201 patients with stage I–IV CRC, by using a 415-gene panel. To analyse the relationship between SMAD4 alteration and other clinicopathological characteristics, we evaluated clinicopathological variables, including invasive-front pathological markers: tumour budding, poorly differentiated cluster, and Crohn-like lymphoid reaction. Fifty-six patients (28%) had SMAD4 alteration: 24 and 32 patients had SMAD4 mutation and deletion, respectively. SMAD4 alteration was significantly associated with T category (P = 0.027), N category (P = 0.037), M category (P = 0.028), and invasive-front pathological markers, such as poorly differentiated cluster grade 3 (P = 0.020) and absence of Crohn-like lymphoid reaction (P = 0.004). Immunohistochemistry revealed that SMAD4 alteration was significantly associated with loss of SMAD4 (P = 0.023). In 90 patients with stage I–III disease, SMAD4 alteration was significantly associated with poor prognosis for relapse-free and overall survival (P = 0.047; P = 0.022, respectively). Conversely, in 111 patients with stage IV disease, SMAD4 alteration was not significantly associated with overall survival. Conclusion: SMAD4 alteration is associated with invasive-front pathological markers and poor prognosis in stage I–III CRC patients.

Original languageEnglish
Pages (from-to)873-882
Number of pages10
JournalHistopathology
Volume74
Issue number6
DOIs
Publication statusPublished - 05-2019

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Histology

Fingerprint Dive into the research topics of 'SMAD4 alteration associates with invasive-front pathological markers and poor prognosis in colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Oyanagi, H., Shimada, Y., Nagahashi, M., Ichikawa, H., Tajima, Y., Abe, K., Nakano, M., Kameyama, H., Takii, Y., Kawasaki, T., Homma, K. I., Ling, Y., Okuda, S., Takabe, K., & Wakai, T. (2019). SMAD4 alteration associates with invasive-front pathological markers and poor prognosis in colorectal cancer. Histopathology, 74(6), 873-882. https://doi.org/10.1111/his.13805